
PHARMACEUTICAL 2017

ARDELYX INC. Rank 168 of 313







PHARMACEUTICAL 2017

ARDELYX INC. Rank 168 of 313



The relative strengths and weaknesses of ARDELYX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARDELYX INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 328% points. The greatest weakness of ARDELYX INC. is the variable Research and Development, reducing the Economic Capital Ratio by 180% points.

The company's Economic Capital Ratio, given in the ranking table, is -209%, being 207% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	203,992
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,201
Liabilities, Non-Current	779
Other Assets	148
Other Compr. Net Income	-71
Other Expenses	0
Other Liabilities	0
Other Net Income	508
Property and Equipment	8,991
Research and Development	94,161
Revenues	0
Selling, General and Administrative Expense	18,734

Output Variable	Value in 1000 USD
Assets	213,131
Liabilities	19,980
Expenses	112,895
Stockholders Equity	193,151
Net Income	-112,387
Comprehensive Net Income	-112,422
Economic Capital Ratio	-209%

